1. Research Priorities in Critical Care Cardiology: JACC Expert Panel.
- Author
-
Miller PE, Huber K, Bohula EA, Krychtiuk KA, Pöss J, Roswell RO, Tavazzi G, Solomon MA, Kristensen SD, and Morrow DA
- Subjects
- Humans, Hospital Mortality, Intensive Care Units, Critical Care, Research, Critical Illness therapy, Critical Illness epidemiology, Coronary Care Units, Cardiology
- Abstract
Over the last several decades, the cardiac intensive care unit (CICU) has seen a substantial evolution in the patient population, comorbidities, and diagnoses. However, the generation of high-quality evidence to manage these complex and critically ill patients has been slow. Given the scarcity of clinical trials focused on critical care cardiology (CCC), CICU clinicians are often left to extrapolate from studies that either exclude or poorly represent the patient population admitted to CICUs. The lack of high-quality evidence and limited guidance from society guidelines has led to significant variation in practice patterns for many of the most common CICU diagnoses. Several barriers, both common to critical care research and unique to CCC, have impeded progress. In this multinational perspective, we describe key areas of priority for CCC research, current challenges for investigation in the CICU, and essential elements of a path forward for the field., Competing Interests: Funding Support and Author Disclosures Drs Bohula and Morrow are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott Laboratories, Abiomed, Amgen, Anthos Therapeutics, Arca Biopharma, AstraZeneca, Daiichi-Sankyo, Intarcia, Janssen, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Regeneron, Roche, Siemens, and Zora Biosciences. Dr Pöss receives institutional research fees from the German Cardiac Society, German Heart Research Foundation, Dr Rolf M. Schwiete Foundation and Getinge. Dr Solomon receives research support from the National Institutes of Health Clinical Center intramural research funds. Dr Kristensen is National Coordinator of the SOS-AMI study (Idorsia departmental grant). Dr Morrow has received consulting fees from Abbott Laboratories, Arca Biopharma, InCarda, Inflammatix, Merck, Novartis, and Roche Diagnostics. Dr Krychtiuk has received speaker fees from Zoll Medical, Sanofi, and Daiichi-Sankyo. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF